Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Aug;13(15):e70068.
doi: 10.1002/cam4.70068.

Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

He Zhao  1   2 , Ying Li  1 , Pengfei Tian  1 , Wei Sun  1 , Yingen Luo  1 , Xiaowu Zhang  1 , Jingui Li  1 , Tao Gong  1 , Zhengqiang Yang  1   3 , Peng Song  2 , Xiao Li  1
Affiliations
Observational Study

Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

He Zhao et al. Cancer Med. 2024 Aug.

Abstract

Background: The efficacy of coronavirus disease 2019 (COVID-19) vaccines in preventing SARS-CoV-2 infection in patients with hepatocellular carcinoma (HCC) is not clear.

Methods: From January 2022 to October 2022, patients diagnosed with HCC in a prospective, multicenter, observational cohort were analyzed.

Results: One hundred and forty-one patients with (n = 107) or without COVID-19 vaccination (n = 34) were included. The number of patients with severe or very severe infection was relatively lower in the vaccinated group (3.7% vs. 11.8%, p = 0.096). Median infection-free survival in the vaccinated group (14.0 vs. 8.3 months, p = 0.010) was significantly longer than that in the unvaccinated group. COVID-19 vaccination (hazard ratio (HR) HR = 0.47), European Cooperative Oncology Group performance score = 0 (HR = 2.06), and extrahepatic spread (HR = 0.28) were found to be the independent predictive factors for infection-free survival.

Conclusion: COVID-19 vaccines could effectively reduce the SARS-Cov-2 infection in patients with HCC.

Keywords: clinical observations; hepatocellular carcinoma; prognosis; vaccine.

PubMed Disclaimer

Conflict of interest statement

All of the authors have no conflict of interests.

Figures

FIGURE 1
FIGURE 1
SARS‐CoV‐2 infection‐free survival and overall survival in patients with hepatocellular carcinoma. (A) SARS‐CoV‐2 infection‐free survival; (B) Overall survival.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209‐249. - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. - PubMed
    1. Sharma A, Patnaik I, Kumar A, Gupta R. COVID‐19 vaccines in patients with chronic liver disease. J Clin Exp Hepatol. 2021;11:720‐726. - PMC - PubMed
    1. Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID‐19 in patients with chronic liver disease: US Multi‐Center Study. Clin Gastroenterol Hepatol. 2021;19:1469‐1479. - PMC - PubMed
    1. Liu F, Feng X, Du J, Ruan M, Liu H. Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection. Cancer Commun. 2023;43:409‐412. - PMC - PubMed

Publication types

Substances